Different surgical and nonsurgical methods are available for AK treatment with patient medical status, lesion number and characteristics, prior treatment, and anatomic location often guiding management decisions. The antineoplastic drug, 5-fluorouracil (5-FU), was first noted for its usefulness in the treatment of AKs in 1962 when patients taking it as a systemic chemotherapy had a subsequent disappearance of their AKs. This led to US FDA approval of topical 5-FU for AK treatment in the 1970s and subsequent development of multiple formulations. It is more useful in the setting of multiple lesions when destructive therapies such as cryosurgery are less helpful.
Immunotherapy. 2012;4(9):939-945. © 2012 Future Medicine Ltd.